Journal article
Update on optimal treatment for metastatic colorectal cancer from the AGITG expert meeting: ESMO congress 2019
DK Lau, M Burge, A Roy, I Chau, DG Haller, JD Shapiro, M Peeters, N Pavlakis, CS Karapetis, NC Tebbutt, E Segelov, TJ Price
Expert Review of Anticancer Therapy | TAYLOR & FRANCIS LTD | Published : 2020
Abstract
Introduction: Outcomes in metastatic colorectal cancer are improving, due to the tailoring of therapy enabled by better understanding of clinical behavior according to molecular subtype. Areas covered: A review of the literature and recent conference presentations was undertaken on the topic of systemic treatment of metastatic colorectal cancer. This review summarizes expert discussion of the current evidence for therapies in metastatic colorectal cancer (mCRC) based on molecular subgrouping. Expert opinion: EGFR-targeted and VEGF-targeted antibodies are now routinely incorporated into treatment strategies for mCRC. EGFR-targeted antibodies are restricted to patients with extended RAS wild-t..
View full abstractGrants
Funding Acknowledgements
This review represents independent research supported by the National Institute for Health Research (NIHR) Biomedical Research Centre at the Royal Marsden NHS Foundation Trust and the Institute of Cancer Research, London. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care.